Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Trial of Ponatinib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST) Following Failure or Intolerance of Prior Therapy With Imatinib

NCT03171389 is registered in ClinicalTrials.gov with Sebastian Bauer as lead sponsor.

NCT NCT03171389
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03171389 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Trial of Ponatinib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST) Following Failure or Intolerance of Prior Therapy With Imatinib
Lead sponsor
Sebastian Bauer
Phase
Phase 2
Overall status
Unknown status
Start date
March 22, 2017
Completion date
September 22, 2020
Enrollment
81 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gist, malignant, kit exon 13 mutation, kit gene mutation